Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

Open access
Helfrich, Iris, Scheffrahn, Inka, Bartling, Sönke, Weis, Joachim, von Felbert, Verena, Middleton, Mark, Kato, Masahi, Ergün, Süleyman, Augustin, Hellmut G., Schadendorf, Dirk · 2010 · Journal of Experimental Medicine

Abstract

Angiogenesis is not only dependent on endothelial cell invasion and proliferation, it also requires pericyte coverage of vascular sprouts for stabilization of vascular walls. Clinical efficacy of angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signaling pathway is still limited to date. We hypothesized that the level of vessel maturation is critically involved in the response to antiangiogenic therapies. To test this hypothesis, we evaluated the vascular network in spontaneously developing melanomas of MT/ret transgenic mice after using PTK787/ZK222584 for anti-VEGF therapy but also analyzed human melanoma metastases taken at clinical relapse in patients undergoing adjuvant treatment using bevacizumab. Both experimental settings showed that tumor vessels, which are resistant to anti-VEGF therapy, are characterized by enhanced vessel diameter and normalization of the vascular bed by coverage of mature pericytes and immunoreactivity for desmin, NG-2, platelet-derived growth factor receptor β, and the late-stage maturity marker α smooth muscle actin. Our findings emphasize that the level of mural cell differentiation and stabilization of the vascular wall significantly contribute to the response toward antiangiogenic therapy in melanoma. This study may be useful in paving the way toward a more rational development of second generation antiangiogenic combination therapies and in providing, for the first time, a murine model to study this.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20091846

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 48

  1. Abramsson, 2003, Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors, J. Clin. Invest., 112, 1142, 10.1172/JCI200318549 · DOI
  2. Andrae, 2008, Role of platelet-derived growth factors in physiology and medicine, Genes Dev., 22, 1276, 10.1101/gad.1653708 · DOI · Paper page
  3. Benjamin, 1998, A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF, Development., 125, 1591, 10.1242/dev.125.9.1591 · DOI · Paper page
  4. Bergers, 2003, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors, J. Clin. Invest., 111, 1287, 10.1172/JCI200317929 · DOI
  5. Betsholtz, 2005, Role of pericytes in vascular morphogenesis, EXS., 94, 115
  6. Carlson, 2001, Direct cell adhesion to the angiopoietins mediated by integrins, J. Biol. Chem., 276, 26516, 10.1074/jbc.M100282200 · DOI · Paper page
  7. Carmeliet, 2005, Angiogenesis in life, disease and medicine, Nature., 438, 932, 10.1038/nature04478 · DOI · Paper page
  8. de Visser, 2006, The inflammatory tumor microenvironment and its impact on cancer development, Contrib. Microbiol., 13, 118, 10.1159/000092969 · DOI · Paper page
  9. Döme, 2002, Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance, J. Pathol., 197, 355, 10.1002/path.1124 · DOI
  10. Erber, 2004, Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms, FASEB J., 18, 338, 10.1096/fj.03-0271fje · DOI · Paper page
  11. Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N. Engl. J. Med., 356, 125, 10.1056/NEJMoa060655 · DOI · Paper page
  12. Fallowfield, 1991, The vascularity of primary cutaneous melanoma, J. Pathol., 164, 241, 10.1002/path.1711640309 · doi:10.1002/path.1711640309
  13. Fiedler, 2004, The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies, Blood., 103, 4150, 10.1182/blood-2003-10-3685 · DOI · Paper page
  14. Gerhardt, 2003, Endothelial-pericyte interactions in angiogenesis, Cell Tissue Res., 314, 15, 10.1007/s00441-003-0745-x · DOI · Paper page
  15. Gupta, 2006, Ultra-high resolution flat-panel volume CT: fundamental principles, design architecture, and system characterization, Eur. Radiol., 16, 1191, 10.1007/s00330-006-0156-y · DOI · Paper page
  16. Hagemann, 2009, Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB, Blood., 113, 3139, 10.1182/blood-2008-12-172825 · DOI · Paper page
  17. Hanahan, 1997, Signaling vascular morphogenesis and maintenance, Science., 277, 48, 10.1126/science.277.5322.48 · DOI · Paper page
  18. Helfrich, 2009, Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma, Clin. Cancer Res., 15, 1384, 10.1158/1078-0432.CCR-08-1615 · DOI · Paper page
  19. Hellström, 1999, Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse, Development., 126, 3047, 10.1242/dev.126.14.3047 · DOI · Paper page
  20. Hess-Stumpp, 2005, PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy, ChemBioChem., 6, 550, 10.1002/cbic.200400305 · DOI
  21. Holash, 1999, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science., 284, 1994, 10.1126/science.284.5422.1994 · DOI · Paper page
  22. Ilmonen, 1999, Prognostic value of tumour vascularity in primary melanoma, Melanoma Res., 9, 273, 10.1097/00008390-199906000-00009 · DOI
  23. Kato, 1998, Transgenic mouse model for skin malignant melanoma, Oncogene., 17, 1885, 10.1038/sj.onc.1202077 · DOI · Paper page
  24. Kiessling, 2004, Volumetric computed tomography (VCT): a new technology for noninvasive, high-resolution monitoring of tumor angiogenesis, Nat. Med., 10, 1133, 10.1038/nm1101 · DOI · Paper page
  25. Kunkel, 2001, Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas, Neuro-oncol., 3, 82, 10.1215/15228517-3-2-82 · doi:10.1215/15228517-3-2-82
  26. Küsters, 2002, Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis, Cancer Res., 62, 341
  27. Leenders, 2002, Design of a variant of vascular endothelial growth factor-A (VEGF-A) antagonizing KDR/Flk-1 and Flt-1, Lab. Invest., 82, 473, 10.1038/labinvest.3780440 · DOI
  28. Leenders, 2002, Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis, Endothelium., 9, 83, 10.1080/10623320212006 · DOI
  29. Maisonpierre, 1997, Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis, Science., 277, 55, 10.1126/science.277.5322.55 · DOI · Paper page
  30. Morikawa, 2002, Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors, Am. J. Pathol., 160, 985, 10.1016/S0002-9440(10)64920-6 · DOI · Paper page
  31. Nasarre, 2009, Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth, Cancer Res., 69, 1324, 10.1158/0008-5472.CAN-08-3030 · DOI · Paper page
  32. Nehls, 1992, Pericyte involvement in capillary sprouting during angiogenesis in situ, Cell Tissue Res., 270, 469, 10.1007/BF00645048 · DOI · Paper page
  33. Neufeld, 1999, Vascular endothelial growth factor (VEGF) and its receptors, FASEB J., 13, 9, 10.1096/fasebj.13.1.9 · DOI · Paper page
  34. Paku, 1998, Current concepts of tumor-induced angiogenesis, Pathol. Oncol. Res., 4, 62, 10.1007/BF02904699 · DOI
  35. Perez, 2009, Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A, Cancer., 115, 119, 10.1002/cncr.23987 · DOI
  36. Pezzella, 1997, Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis, Am. J. Pathol., 151, 1417
  37. Pichiule, 2004, Hypoxic regulation of angiopoietin-2 expression in endothelial cells, J. Biol. Chem., 279, 12171, 10.1074/jbc.M305146200 · DOI · Paper page
  38. Scharpfenecker, 2005, The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism, J. Cell Sci., 118, 771, 10.1242/jcs.01653 · DOI · Paper page
  39. Shieh, 2009, Tumor-associated macrophage correlated with angiogenesis and progression of mucoepidermoid carcinoma of salivary glands, Ann. Surg. Oncol., 16, 751, 10.1245/s10434-008-0259-6 · doi:10.1245/s10434-008-0259-6
  40. Siemeister, 1998, An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells, Proc. Natl. Acad. Sci. USA., 95, 4625, 10.1073/pnas.95.8.4625 · DOI
  41. Suri, 1996, Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis, Cell., 87, 1171, 10.1016/S0092-8674(00)81813-9 · DOI · Paper page
  42. Sweeney, 2002, Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production, Clin. Cancer Res., 8, 2714
  43. Thomas, 2007, A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer, Ann. Oncol., 18, 782, 10.1093/annonc/mdl469 · DOI
  44. von Tell, 2006, Pericytes and vascular stability, Exp. Cell Res., 312, 623, 10.1016/j.yexcr.2005.10.019 · DOI · Paper page
  45. Weis, 1989, Differential effects of nerve, muscle, and fat tissue on regenerating nerve fibers in vivo, Muscle Nerve., 12, 723, 10.1002/mus.880120905 · DOI
  46. Weis, 1995, Nerve conduction changes and fine structural alterations of extra- and intrafusal muscle and nerve fibers in streptozotocin diabetic rats, Muscle Nerve., 18, 175, 10.1002/mus.880180205 · DOI
  47. Wong, 1997, Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues, Circ. Res., 81, 567, 10.1161/01.RES.81.4.567 · DOI · Paper page
  48. Wood, 2000, PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration, Cancer Res., 60, 2178

Cited by

See all 170

Metadata

Authors
Helfrich, I., Scheffrahn, I., Bartling, S., Weis, J., von Felbert, V., Middleton, M., Kato, M., Ergün, S., Augustin, H. G., & Schadendorf, D.
Venue
Journal of Experimental Medicine
Published
2010-03-01
Volume
207
Issue
3
Pages
491-503
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W3025821417
Cited by
170
References
9
FWCI
7.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.